Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice.
The immunogenicity and protective efficacy of an influenza A subunit vaccine preparation administered to mice in an aqueous form, or presented as immunostimulatory complexes (ISCOMs), liposomes or with Freund's complete adjuvant (FCA), were assessed in comparative studies with live infectious virus. Both intranasal and parenteral routes of administration were assessed. An enzyme-linked immunosorbent assay (ELISA) was used to measure nasal wash and serum antibody responses in groups of unprimed mice, while protection was determined by the recovery of homologous influenza virus from mouse nasal washes and lung homogenates following challenge infection by the intranasal route. The results showed that parenteral administration of the influenza antigen preparations induced variable levels of both local and systemic antibodies at weeks 3, 7 and 22 postimmunization. Although the overall greatest levels of antibody and protection were elicited in mice following live virus infection, formulation of influenza surface haemagglutinin (HA) and neuraminidase (NA) proteins into ISCOMs elicited high and persistent antibody responses and provided relatively good protection of the upper and lower respiratory tracts of these animals. The results also show a relatively poor effect of the subunit antigen preparations in promoting humoral immune responses and protection irrespective of the nature of their presentation, when given by the intranasal route.
Ben Ahmeida
E T
ET
Department of Experimental and Clinical Microbiology, University of Sheffield Medical School, UK.
Gregoriadis
G
G
Potter
C W
CW
Jennings
R
R
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000906:Antibodies / Q000032:analysis; D000917:Antibody Formation / Q000187:drug effects*; D000956:Antigens, Viral / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology; D004337:Drug Carriers; D005260:Female; D005620:Freund's Adjuvant / Q000494:pharmacology*; D016882:ISCOMs / Q000494:pharmacology*; D007070:Immunoglobulin A / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000096:biosynthesis; D009980:Influenza A virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000494:pharmacology*; D008081:Liposomes / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009296:Nasal Cavity / Q000276:immunology; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control*
D000276:Adjuvants, Immunologic; D000906:Antibodies; D000956:Antigens, Viral; D004337:Drug Carriers; D016882:ISCOMs; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007252:Influenza Vaccines; D008081:Liposomes; D005620:Freund's Adjuvant